CELLPRO AND CORANGE CONCLUDE COLLABORATION.SEATTLE--(BUSINESS WIRE)--July 31, 1995--CellPro Inc. (Nasdaq:CPRO CPRO Columbia Pike Revitalization Organization CPRO Connecticut Peer Review Organization, Inc. ) and Corange International Ltd. today announced that effective July July: see month. 31, 1995, the two companies have reached a definitive agreement to conclude their collaboration Working together on a project. See collaborative software. entered into in December December: see month. 1993. Under the new agreement, Corange is paying CellPro $30 million in exchange for certain rights of supply and one million newly issued shares of CellPro common stock. CellPro is supporting Corange in the development and commercialization of gene medicine for world-wide markets by supplying CellPro CEPRATE Ceprate® Oncology A product line that selectively removes cell lines–eg, stem cells from BM and peripheral blood before tumor-purging therapy, or removes T cells to ↓ GVHD in allograft recipients. See Marrow ablation. systems on a non-exclusive basis. Diagnostic and therapeutic rights in CellPro technology previously subject to the 1993 agreements are being returned to CellPro and such agreements are terminated. The two companies have exchanged releases in settlement of all claims relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the 1993 agreements. Richard D. Murdock, president and chief executive officer of CellPro stated, "This is a constructive way to resolve the differences that had arisen between our two companies under the 1993 agreements. We are looking forward to having Corange as one of our customers in the gene therapy field." CellPro Inc. is a Bothell, Wash.-based company specializing in developing, manufacturing and marketing proprietary continuous-flow, cell-selection systems for use in a variety of therapeutic, diagnostic and research applications. CONTACT: CellPro Inc. Lee M. Parker, 206/485-7644, Home: 206/820-4121 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion